A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Who May Qualify: - willing to sign a consent form / assent obtained - Must have completed Week 52 on treatment on core study and must be \< 18 years of age at the time the willing to sign a consent form document is signed - Age and sex specific body mass index (BMI) no lower in range than the 5th percentile on Centers for Disease Control (CDC growth chart) at enrollment - Willing to adhere to study visit schedule and protocol requirements - Must have acceptable benefit/risk for continued treatment with apremilast Who Should NOT Join This Trial: - Answer "yes" to any question on C-SSRS at Week 52 visit of core study - Scheduled surgery or other interventions that would interrupt study participation - Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for 30 days after last dose - Female participants planning to become pregnant while on study through 30 days after last dose - Female participants of childbearing potential with positive pregnancy test at Week 0 - Known sensitivity to any products to be administered during dosing Always talk to your doctor about whether this trial is right for you.